Logo-bi
Original Research

1. Silibinin exhibits anti-tumor effects in a breast cancer stem cell model by targeting stemness and induction of differentiation and apoptosis

Javad Firouzi ORCID, Fattah Sotoodehnejadnematalahi, Alireza Shokouhifar ORCID, Mahsa Rahimi, Niloufar Sodeifi, Parisa Sahranavardfar, Masoumeh Azimi, Ehsan Janzamin, Majid Safa, Marzieh Ebrahimi* ORCID
BioImpacts. 2022;12(5): 415-429. doi: 10.34172/bi.2022.23336
PMCID: PMC9596878     PMID: 36381630     Scopus ID: 85140213651    
Article
PDF
Suppl 1
Full Text
XML
Cited By:
4
0
6
The effect of silibinin evaluated on self-renewal, tumorgenicity, and metastasis potential of Mammospheres derived from MCF-7, MDA-MB231 cell lines, and MDA-MB468 aggregated cells
Original Research

2. Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer
Laura Cabeza ORCID, Mazen M. El-Hammadi ORCID, Raul Ortiz ORCID, Maria D. Cayero-Otero, Julia Jiménez-López ORCID, Gloria Perazzoli ORCID, Lucia Martin-Banderas ORCID, Jose M. Baeyens ORCID, Consolación Melguizo* ORCID, Jose Prados ORCID
BioImpacts. 2022;12(6): 515-531. doi: 10.34172/bi.2022.23433
PMCID: PMC9809141     PMID: 36644541     Scopus ID: 85140308481    
Article
PDF
Suppl 1
Full Text
XML
Cited By:
5
0
4
These results suggest that our PTX-PLGA NPs could be a suitable strategy for breast cancer therapy, improving antitumor drug efficiency and reducing systemic toxicity without altering its mechanism of action.
Original Article

3. Growth and invasion inhibition of T47D ductal carcinoma cells by the association of docetaxel with a bioactive agent in neutral nanosuspension
Raghdah S. Bawadud ORCID, Mayson H. Alkhatib* ORCID
Bioimpacts. 2023;13(2): 145-157. doi: 10.34172/bi.2023.23515
PMCID: PMC10182446     PMID: 37193079     Scopus ID: 85152114664    
Article
PDF
Full Text
XML
Cited By:
4
1
3
Co-delivery of NE-DTX+TQ may probably inhibit the proliferation of T47D via the induction of apoptosis and autophagy pathways and impede the migration by reducing the BCSC population and downregulating TWIST-1 expression to decrease the epithelial-to-mesenchymal transition (EMT) of breast cancer cells

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge